CG Oncology, Inc.
Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
Countdown
267days
Phase 2 readout · ~ Mar 31, 2027 estimated
What's at stake
Phase 2 trial results for Cretostimogene Grenadenorepvec in High-Risk Non-Muscle-Invasive Bladder Cancer are due ~ Mar 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06567743: Phase 2 trial, sponsor CG Oncology, Inc., drug Cretostimogene Grenadenorepvec. Primary completion date 2027-03-31 (estimated).”